Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Current Market Cap

<< Previous

Bullboard Posts

Next >>

Comment by Riverfolkon May 18, 2021 1:10pm

120 Views

Post# 33222660

RE:Current Market Cap

In addition to my previous post, we are still currently trading below the last straight equity financing at $1.50 and the following has occured:

-Additional Canadian hospitals added
-Health Canada Ammended Phase II trial Protocol
-Turkey Ministry of Health Approval for trial expansion
-Licensing aggreement for Cilistatin
-Final Dosing of Phase II Metablok trial (65 patients enrolled)

Riverfolk wrote: The recent sell off by a motivated ANON has placed the current market cap at pre-LSALT catalyst levels. $1.21 is:

-Pre-Health Canada Approval
-Pre-Turkish Ministry of Health Approval
-Pre- FDA Approval
-Pre-Government of Canada Funding
-Pre- Phase 2 trial Expansion

The last straight equity financing was at $1.50